New cell therapy trial hopes to tame Hard-to-Treat myeloma
NCT ID NCT04155749
First seen Feb 19, 2026 · Last updated May 01, 2026 · Updated 9 times
Summary
This early-phase study tests experimental cell therapies in 40 people with multiple myeloma that has returned or not responded to at least three prior treatments. The main goals are to check safety and find the best dose. Participants must have measurable disease and adequate organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Cellular Therapeutics Facility, DCAM 0800A
Chicago, Illinois, 60637, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Froedtert Hospital/Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.